This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6ehy
From Proteopedia
(Difference between revisions)
m (Protected "6ehy" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery== | |
| - | + | <StructureSection load='6ehy' size='340' side='right' caption='[[6ehy]], [[Resolution|resolution]] 2.25Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6ehy]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EHY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6EHY FirstGlance]. <br> | |
| - | + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ehy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ehy OCA], [http://pdbe.org/6ehy PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ehy RCSB], [http://www.ebi.ac.uk/pdbsum/6ehy PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ehy ProSAT]</span></td></tr> | |
| - | [[ | + | </table> |
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Hargreaves, D]] | [[Category: Hargreaves, D]] | ||
| + | [[Category: Abvance]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Pistoia alliance]] | ||
| + | [[Category: Scfv]] | ||
Revision as of 07:56, 8 November 2017
scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery
| |||||||||||
